COMPASS Pathways presents largest ever study of psilocybin therapy, at American Psychiatric Association annual meeting May 23, 2022
Numinus Wellness Receives Health Canada Special Access Program Applicant Approval to Provide Psychedelic-assisted… May 16, 2022
COMPASS Pathways plc announces first quarter 2022 financial results and business highlights May 10, 2022
COMP360 Psilocybin Therapy Shows Potential In Exploratory Open-Label Studies For Anorexia Nervosa And Severe… May 3, 2022
atai Life Sciences Announces Fourth Quarter and Full Year 2021 Financial Results, Reports on R&D Progress and… Mar 30, 2022
Two Thirds Of Physicians Surveyed Believe Psilocybin Therapy Has Potential Benefit For Patients With Treatment-Resistant… Jan 19, 2022
atai Life Sciences announces FDA Investigational New Drug (IND) Clearance for PCN-101 R-ketamine Program Jan 12, 2022
MYND Life Sciences Provides Update on Depression Gene Modulation Pathway Patent Application Dec 15, 2021
COMPASS Pathways announces positive outcome of 25mg COMP360 psilocybin therapy as adjunct to SSRI antidepressants in… Dec 13, 2021
